Wednesday, February 10, 2010, 2:11pm SGT - The Singapore stock market closes in 2 hours and 49 minutes.
To create a watchlist or portfolio of shares, Register
FINANCE HOME PAGEINVESTINGFINANCE NEWS
    Market:       |  

Achillion Pharmaceuticals, Inc. (ACHN)

At 5:00AM SGT: 2.37 USD  Down 0.05 (2.07%)  
 MORE ON ACHN 
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
 Achillion Pharmaceuticals, Inc. (NGM:ACHN) Delayed quote dataEdit
Last Trade:2.37 USD
Trade Time:5:00AM SGT
Change:Down 0.05 (2.07%)
Prev Close:2.42
Open:2.46
Bid:2.28 x 500
Ask:2.54 x 500
1y Target Est:6.40
Day's Range:2.32 - 2.51
52wk Range:1.10 - 3.89
Volume:344,536
Avg Vol (3m):706,902
Market Cap:63.17M
P/E (ttm):N/A
EPS (ttm):-1.05
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y 
Use Y! Toolbar to track stocks
 Add ACHN to Portfolio   Download Data

 HEADLINES 
•Achillion to Present at 12th Annual BIO CEO and Investor Conference
GlobeNewswire (Tue 5:00am)
•China Biotech Week in Review: New Investments in Life Science
at Seeking Alpha (Mon, Feb 8)
•Achillion Pharma Out-Licensed China Rights for HIV, Hepatitis Treatment
at Seeking Alpha (Thu, Feb 4)
•ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
EDGAR Online (Thu, Feb 4)
•Ann Taylor, Lexmark, Achillion Pharma big movers
AP (Wed, Feb 3)
•Achillion Announces Closing of Underwriters' Over-Allotment Option
GlobeNewswire (Wed, Feb 3)
•Movers roundup: Rudolph Technologies, Hologic
AP (Wed, Feb 3)
•ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial
EDGAR Online (Wed, Feb 3)
•Achillion rises on hepatitis/HIV drug pact
AP (Wed, Feb 3)
•Achillion shares rise on drug development deal in China
at Reuters (Tue, Feb 2)
•Achillion Pharma upgraded by Wedbush Morgan
Briefing.com (Tue, Feb 2)
•Achillion Announces License Agreement for Elvucitabine Development in China
GlobeNewswire (Tue, Feb 2)
More Headlines for ACHN...
 ANALYST 
EPS Est (next year) (Dec-09) :-0.94
EPS Est (in 2 years) (Dec-10) :-0.60
Avg Rec (current)*:2.0
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Achillion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for infectious diseases.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Search by Company
•Latest News•Singapore Indices